IREN LTD (IREN)

AU0000185993 - Common Stock

11.81  +0.56 (+4.98%)

Premarket: 11.44 -0.37 (-3.13%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IREN. IREN was compared to 280 industry peers in the Software industry. While IREN seems to be doing ok healthwise, there are quite some concerns on its profitability. IREN is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!



Quickly go to:

1

1. Profitability

1.1 Basic Checks

IREN had negative earnings in the past year.
In the past 5 years IREN always reported negative net income.
Of the past 5 years IREN 4 years had a positive operating cash flow.

1.2 Ratios

IREN has a Return On Assets (-5.88%) which is comparable to the rest of the industry.
IREN has a Return On Equity (-6.67%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -5.88%
ROE -6.67%
ROIC N/A
ROA(3y)-42.61%
ROA(5y)-38.24%
ROE(3y)-51.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

IREN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

IREN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IREN has been increased compared to 1 year ago.
Compared to 1 year ago, IREN has an improved debt to assets ratio.

2.2 Solvency

IREN has an Altman-Z score of 9.31. This indicates that IREN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 9.31, IREN is doing good in the industry, outperforming 77.42% of the companies in the same industry.
IREN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IREN has a better Debt to Equity ratio (0.00) than 65.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.31
ROIC/WACCN/A
WACC11.87%

2.3 Liquidity

IREN has a Current Ratio of 1.09. This is a normal value and indicates that IREN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.09, IREN is not doing good in the industry: 73.48% of the companies in the same industry are doing better.
IREN has a Quick Ratio of 1.09. This is a normal value and indicates that IREN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IREN (1.09) is worse than 72.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.75% over the past year.
The Revenue has grown by 149.98% in the past year. This is a very strong growth!
Measured over the past years, IREN shows a very strong growth in Revenue. The Revenue has been growing by 188.02% on average per year.
EPS 1Y (TTM)90.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)149.98%
Revenue growth 3Y188.02%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 292.73% on average over the next years. This is a very strong growth
Based on estimates for the next years, IREN will show a very strong growth in Revenue. The Revenue will grow by 94.00% on average per year.
EPS Next Y710.45%
EPS Next 2Y589.51%
EPS Next 3Y292.73%
EPS Next 5YN/A
Revenue Next Year178.85%
Revenue Next 2Y128.37%
Revenue Next 3Y94%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

IREN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 8.03, which indicates a very decent valuation of IREN.
Based on the Price/Forward Earnings ratio, IREN is valued cheaply inside the industry as 96.42% of the companies are valued more expensively.
IREN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.99.
Industry RankSector Rank
PE N/A
Fwd PE 8.03

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IREN's earnings are expected to grow with 292.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y589.51%
EPS Next 3Y292.73%

More info and screens

0

5. Dividend

5.1 Amount

IREN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IREN LTD

NASDAQ:IREN (12/24/2024, 8:21:31 PM)

Premarket: 11.44 -0.37 (-3.13%)

11.81

+0.56 (+4.98%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-26 2024-11-26/amc
Earnings (Next)N/A N/A
Inst Owners43.18%
Inst Owner ChangeN/A
Ins Owners5.21%
Ins Owner ChangeN/A
Market Cap2.53B
Analysts82.5
Price Target18.3 (54.95%)
Short Float %5.1%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-604.83%
Min EPS beat(2)-1085.5%
Max EPS beat(2)-124.16%
EPS beat(4)1
Avg EPS beat(4)-800.99%
Min EPS beat(4)-2023.39%
Max EPS beat(4)29.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-6.65%
Max Revenue beat(2)-3.19%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-6.65%
Max Revenue beat(4)3.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.81%
PT rev (3m)-0.74%
EPS NQ rev (1m)-75.72%
EPS NQ rev (3m)-75.72%
EPS NY rev (1m)-55.37%
EPS NY rev (3m)-54.9%
Revenue NQ rev (1m)-9.23%
Revenue NQ rev (3m)-9.23%
Revenue NY rev (1m)15.09%
Revenue NY rev (3m)12.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.03
P/S 12.13
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB 2.24
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)1.47
Fwd EY12.46%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.97
BVpS5.27
TBVpS5.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.88%
ROE -6.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.61%
ROA(5y)-38.24%
ROE(3y)-51.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z 9.31
F-ScoreN/A
WACC11.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)123.51%
Cap/Sales(5y)130.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y710.45%
EPS Next 2Y589.51%
EPS Next 3Y292.73%
EPS Next 5YN/A
Revenue 1Y (TTM)149.98%
Revenue growth 3Y188.02%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year178.85%
Revenue Next 2Y128.37%
Revenue Next 3Y94%
Revenue Next 5YN/A
EBIT growth 1Y44.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4085.96%
EBIT Next 3Y375.87%
EBIT Next 5YN/A
FCF growth 1Y18.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y771.34%
OCF growth 3Y210.56%
OCF growth 5YN/A